158 related articles for article (PubMed ID: 35217798)
1. Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours.
Farrer NJ; Higgins GS; Kunkler IH
Br J Cancer; 2022 May; 126(9):1241-1243. PubMed ID: 35217798
[TBL] [Abstract][Full Text] [Related]
2. Switching on prodrugs using radiotherapy.
Geng J; Zhang Y; Gao Q; Neumann K; Dong H; Porter H; Potter M; Ren H; Argyle D; Bradley M
Nat Chem; 2021 Aug; 13(8):805-810. PubMed ID: 34112990
[TBL] [Abstract][Full Text] [Related]
3. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug.
Cho YS; Chung SW; Kim HR; Won TH; Choi JU; Kim IS; Kim SY; Byun Y
J Control Release; 2019 Feb; 296():241-249. PubMed ID: 30659905
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs in genetic chemoradiotherapy.
Patterson AV; Saunders MP; Greco O
Curr Pharm Des; 2003; 9(26):2131-54. PubMed ID: 14529410
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
7. Radioluminescent nanoparticles for radiation-controlled release of drugs.
Misra R; Sarkar K; Lee J; Pizzuti VJ; Lee DS; Currie MP; Torregrosa-Allen SE; Long DE; Durm GA; Langer MP; Elzey BD; Won YY
J Control Release; 2019 Jun; 303():237-252. PubMed ID: 31026550
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy-assisted tumor selective metronomic oral chemotherapy.
Chung SW; Kweon S; Lee BS; Kim GC; Mahmud F; Lee H; Cho YS; Choi JU; Jeon OC; Kim JW; Kim SW; Kim IS; Kim SY; Byun Y
Int J Cancer; 2017 Nov; 141(9):1912-1920. PubMed ID: 28635011
[TBL] [Abstract][Full Text] [Related]
9. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.
Chung SW; Choi JU; Lee BS; Byun J; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Biomaterials; 2016 Jul; 94():1-8. PubMed ID: 27085176
[TBL] [Abstract][Full Text] [Related]
10. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Shibamoto Y; Sugie C; Ito M; Ogino H
Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
[TBL] [Abstract][Full Text] [Related]
11. [Chemoradiotherapy of solid tumours in the adult: current views and perspectives].
Noël G; Mazeron JJ; Favaudon V
Bull Cancer; 2003 Jan; 90(1):85-92. PubMed ID: 12609809
[TBL] [Abstract][Full Text] [Related]
12. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
Rich TA; Shepard RC; Mosley ST
J Clin Oncol; 2004 Jun; 22(11):2214-32. PubMed ID: 15169811
[TBL] [Abstract][Full Text] [Related]
13. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Milas L; Mason KA; Crane CH; Liao Z; Masferrer J
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):15-24. PubMed ID: 12800601
[TBL] [Abstract][Full Text] [Related]
14. [Radiotherapy in cancers of the oesophagus, the gastric cardia and the stomach].
Créhange G; Huguet F; Quero L; N'Guyen TV; Mirabel X; Lacornerie T
Cancer Radiother; 2016 Sep; 20 Suppl():S161-8. PubMed ID: 27523409
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X; Warner SB; Wagner KT; Caster JM; Zhang T; Ohana P; Gabizon AA; Wang AZ
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):547-55. PubMed ID: 27681751
[TBL] [Abstract][Full Text] [Related]
16. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
Yoon KJ; Potter PM; Danks MK
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
[TBL] [Abstract][Full Text] [Related]
17. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
Patterson AV; Williams KJ; Cowen RL; Jaffar M; Telfer BA; Saunders M; Airley R; Honess D; van der Kogel AJ; Wolf CR; Stratford IJ
Gene Ther; 2002 Jul; 9(14):946-54. PubMed ID: 12085243
[TBL] [Abstract][Full Text] [Related]
18. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
19. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
[TBL] [Abstract][Full Text] [Related]
20. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Niyazi M; Belka C; Manapov F
Eur J Cancer; 2019 Feb; 108():50-54. PubMed ID: 30648629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
